Lyell Immunopharma Reports FY2025 Results, Advances Key CAR T-Cell Programs, and Secures $50M Financing

summarizeSummary

Lyell Immunopharma reported an improved net loss for FY2025, initiated a Phase 3 trial for its lead CAR T-cell therapy, acquired a new solid tumor asset with promising early data, and secured $50 million in equity financing, extending its cash runway into Q2 2027, though accompanied by significant share dilution.

check_boxKey Events

• FY2025 Financial Results Confirmed

  Lyell Immunopharma reported a net loss of $274.45 million for fiscal year 2025, an improvement from $342.99 million in 2024, with minimal revenue of $36,000. Cash, cash equivalents, and marketable securities stood at $247.2 million as of December 31, 2025, providing a runway into Q2 2027.

• Lead CAR T-Cell Program Advances to Phase 3

  The company initiated a Phase 3 randomized controlled head-to-head clinical trial (PiNACLE-H2H) for its lead product candidate, ronde-cel (LYL314), in second-line large B-cell lymphoma (LBCL). Positive Phase 1/2 data showed a 93% overall response rate and 76% complete response rate in 3L+ LBCL patients, with a manageable safety profile.

• Strategic Acquisition of Solid Tumor CAR T-Cell Asset

  In November 2025, Lyell acquired exclusive global rights to LYL273, a GCC-targeted CAR T-cell product candidate for metastatic colorectal cancer (mCRC), for $40 million cash and 1.9 million shares. Early Phase 1 data for LYL273 showed a 67% overall response rate and 8-month median progression-free survival at the highest dose level, with Fast Track designation from the FDA.

• Enhanced Liquidity with Recent Equity Financing

  A subsequent event on March 6, 2026, saw the company issue 1,952,360 shares of common stock for gross proceeds of $50 million through a Securities Purchase Agreement (SPA) put right, further strengthening its financial position.

auto_awesomeAnalysis

Lyell Immunopharma's 2025 annual report confirms a substantial net loss of $274.45 million, an improvement from the prior year, with minimal revenue. Despite ongoing losses, the company has extended its cash runway into Q2 2027, significantly bolstered by a recent $50 million equity financing completed in March 2026. A major highlight is the advancement of its lead CAR T-cell candidate, ronde-cel, into a Phase 3 head-to-head clinical trial for large B-cell lymphoma, supported by positive Phase 1/2 data. Additionally, the company strategically acquired exclusive global rights to LYL273, a promising GCC-targeted CAR T-cell candidate for metastatic colorectal cancer, which has shown encouraging early-stage clinical activity. This acquisition involved a $40 million cash payment and the issuance of 1.9 million shares, with potential for significant future milestone payments. While these strategic moves and financing efforts are crucial for pipeline development and extending operational runway, they have resulted in substantial share dilution from recent equity issuances and acquisitions.